NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, has validated and launched the first two of a series of next generation cancer profiling tests.  These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumour cancers.  Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months.

The MDS next generation sequencing (NGS) test can be performed on bone marrow, peripheral blood and plasma samples.  Plasma-based testing for MDS may be used to avoid bone marrow biopsies.  It also has the potential to quantify and monitor tumour load and to detect the emergence of subclones.  The MDS next generation profiling test covers 16 genes involved in the various pathways of MDS, including epigenomics, signal transduction, transcription regulation and spliceosomes.  This test is particularly important for confirming and defining the diagnosis of MDS, which can be extremely difficult in early stages of the disease.

The solid tumour cancer NGS profiling test covers 48 genes and is performed on paraffin-embedded tissue.  This solid tumour profile is extensive and covers the driver genes involved in various types of solid tumour cancers.

Doug VanOort, the company's chairman and CEO, said, "NeoGenomics is committed to developing and using cutting edge technology to provide efficient and reliable clinical tests.  We believe that targeted next generation sequencing technology has advanced sufficiently to be offered more routinely in high-throughput clinical laboratory testing for cancer patients.  Importantly, our NGS tests focus on the actionable genes justified medically and financially at this time.  Our NGS profiles are designed for precision testing in order to generate actionable data.  Each of these tests is relevant for diagnosis, predicting prognosis, determining or monitoring therapy, and exploring clinical trials options."

Dr Maher Albitar, the company's chief medical officer and director of research and development, commented, "While we do not believe that whole genome or exome NGS is ready for high throughput clinical laboratory testing, targeted NGS provides significant advantages over conventional technology. In fact, the more limited the number of genes analyzed, the more reliable the NGS testing.  Our panel of 16 genes for MDS provides remarkable precision, reliability and sensitivity for the diagnosis, monitoring and management of patients with MDS, especially when performed on peripheral blood plasma. Next generation sequencing is allowing us to further establish plasma-based testing as a practical and more routine testing in haematologic neoplasms."

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry.